Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + Pucotenlimab for Stage IVB Oral/Oropharyngeal Squamous Cell Carcinoma
NCT07844551Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 2 trial of becotatug vedotin in oral squamous cell carcinoma (OSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Huashan Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07844551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844551.